C54
Conditions
Interventions
Group 1: Therapy of endometrial cancer according to current guidelines
follow-up visits 6, 12 and 24 months after surgery as well as annual follow up from 24 months on
Group 2: Therapy of endometrial
Sponsors
Universitätsklinikum Essen
Eligibility
Sex/Gender
Female
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Histologically proven endometrial carcinoma: endometroid and non-endometroid FIGO stages I-III; Karnofsky-Index = 70; unrestricted operability; Age >=18 years. - Completed treatment with according Cohort A, PMMR/targeted compartmental pelvic/paraaortic +/- complete pelvic and paraaortic LNE without adjuvant radiotherapy by the responsible clinic (clinician). or - Completed treatment according Cohort B, current clinical practice including adjuvant treatment based on ESMO/ESGO/ESTRO guidelines [26] by the responsible clinic (clinician). - Informed consent of the patient
Exclusion criteria
Exclusion criteria: Uterine pure sarcoma - Distant metastases; sclerodermia, lupus erythematodes, mixed connective tissue disease; secondary malignancy; previous radiotherapy of the pelvis. - Pregnancy - Patients with diseases of the connective tissue will be excluded because of unforeseeable (e.g. neurological) symptoms and disorders after surgery. - Postoperative radiotherapy could be administered with respect to the surgical field in R1 situation or if >= 5 lymph nodes were involved; in all other situations adjuvant radiotherapy will be an exclusion criterion for participation in the study cohort A.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-free Survival | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall Survival QOL (EORTC QLQ-C30, SAQ, German Pelvic Floor Questionnaie, Lymphedema-Questionnaire). | — |
Countries
Germany, Sweden
Contacts
Public ContactKatharina Denzel
Universitätsfrauenklinik Essen Studiensekretariat
Outcome results
None listed